Sign in
Taking people in United StatesNo phase

Studies people living with HIV and their samples over time

Collects samples and health data from adults with HIV-1 to study the virus.

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Registry title
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
Status
Recruiting
People taking part
2,500 people, planned
Started
Mar 2000
Expected to end
Dec 2033
Type of study
Observational
Record updated
8 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with HIV-1 who fit one of four groups, such as people not on HIV medicine or people about to start it. It follows them over time and stores samples.

Age
18 years or older
Sex
All sexes can join.
Disease stage
HIV-1 infection. People can join with one of these: viral load under 2000 copies/ml without HIV medicine; undetectable viral load on stable medicine with CD4 T-cells consistently under 350 for the last 12 months; never treated and planning to start; or HIV-positive 10 years or more without treatment and CD4 always above 500.
Earlier treatment
Some groups must be on a stable HIV medicine regimen. Some must have had no HIV medicine, or none for 10 years or more. One group has never taken HIV medicine and plans to start.
Biomarker or test result
HIV viral load and CD4 T-cell counts, as listed in each group.

Main reasons for not taking part

  • Active opportunistic infection, or treatment for one in the last 4 months (oral candidiasis is acceptable)
  • Active treatment for cancer
  • Active treatment for hepatitis C that needs interferon-based therapy
  • Immunosuppressive therapy in the last 4 months

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:
  • Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
  • Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen
  • Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable
  • Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500

Who cannot take part

  • Immunosuppressive therapy taken within the last 4 months
  • Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
  • Active treatment for cancer
  • Active treatment for hepatitis C requiring interferon based therapy

Where in United States

  • San Francisco General HospitalSan Francisco, United StatesContact: Rebecca Hoh, M.S.Taking people

About the trial

What the trial wants to find out

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
Plain-language title
Studies people living with HIV and their samples over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
8 September 2026